The biomanufacturing industry is growing rapidly and becoming one of the key drivers of personalized medicine and life science. However, biopharmaceutical production faces critical challenges, including complexity, high variability, long lead time and rapid changes in technologies, processes, and regulatory environment. Driven by these challenges, we explore the bio-technology domain knowledge and propose a rigorous risk and sensitivity analysis framework for biomanufacturing innovation. pretable risk and sensitivity analysis. Thus, the proposed framework can provide the science-and risk-based guidance on the process monitoring, data collection, and process parameters specifications to facilitate the production process learning and stability control.
Built on the causal relationships of raw material quality attributes, production process, and bio-drug properties in safety and efficacy, we develop a Bayesian Network (BN) to model the complex probabilistic interdependence between process parameters and quality attributes of raw materials/in-process materials/drug substance. It integrates various sources of data and leads to an interpretable probabilistic knowledge graph of the end-to-end production process. Then, we introduce a systematic risk analysis to assess the criticality of process parameters and quality attributes. The complex production processes often involve many process parameters and quality attributes impacting on the product quality variability. However, the real-world (batch) data are often limited, especially for customized and personalized bio-drugs. We propose uncertainty quantification and sensitivity analysis to analyze the impact of model risk. Given very limited process data, the empirical results show that we can provide reliable and inter-key limitations. First, as far as we know, the existing OR approaches introduced for biomanufacturing still focus on developing general methodologies, and they do not fully explore the pharmaceutical biotechnology domain knowledge (e.g., the underlying physical mechanics causing the interdependence of raw material quality, production process, and bio-drug properties in safety and efficacy). For complex biopharmaceutical production process which often has tight batch data, this limits OR methodology performance and interpretability, as well as its adoption in real applications. Second, the existing approaches tend to focus on a certain (limited) part of the biomanufacturing system and there is no appropriate and reliable end-to-end risk analysis and control framework. Some recent works, e.g., Martagan et al. (2016 Martagan et al. ( , 2017 Martagan et al. ( , 2018 , incorporate physical-chemical characteristics and develop Markov decision models to find the optimal operational policies with the scope limited in fermentation and chromatography.
For complex systems, Bayesian network (BN) can be used to combine expert knowledge and data. It can facilitate the end-to-end data integration and analysis in various applications, including additive manufacturing (Wang et al., 2018) , gene co-expression (Troyanskaya et al., 2003) , information system security (Feng et al., 2014) and etc.
Besides, global probabilistic sensitivity analysis can evaluate the contribution of each random input to the variation of output; see the review in Borgonovo & Plischke (2016) .
Since the commonly used variance-based sensitivity measures (i.e., first-order effects and total effects) fail to adequately account for probabilistic dependence and structural interactions, Owen (2014) and Song et al. (2016) introduce and study a new sensitivity measure, called Shapley value (SV), which is motivated by game theory.
Driven by the critical challenges in biomanufacturing, in this paper, we propose a new BN based risk and sensitivity analysis framework for end-to-end production process risk management. It can overcome the key limitations of existing OR methodologies. By exploring the causal relationships of raw material quality, production process, and bio-drug properties in safety and efficacy, we first introduce a relational graph that can meaningfully integrate all the data collected from the production processes. Then, we develop a BN modeling the underlying probabilistic interdependence of critical process parameters (CPPs) and critical quality attributes (CQAs) of raw materials/inprocess materials/Active Pharmaceutical Ingredients (API). After that, we propose a production process risk analysis to study the contribution of each CPP/CQA to the output variance and assess their criticality. Since the BN is estimated from limited real-world batch data, there exists the model risk (MR) . We further introduce uncertainty quantification (UQ) and sensitivity analysis (SA) to study the impact of MR on the production process risk analysis. Thus, the proposed framework can facilitate the systematic learning and guide the science-and risk-based process monitoring and CPPs/CQAs specification to improve the production process stability. This paper is organized as follows. In Section 2, we present the problem description. Then, we propose a production process risk analysis in Section 3, and further introduce BN based uncertainty quantification and sensitivity analysis in Section 4.
We conduct the empirical study in Section 5 and conclude this paper in Section 6.
Problem Description and Proposed Framework
We propose a systematic BN-SV-MR based risk and sensitivity analysis framework to facilitate the understanding and stability control for end-to-end biopharmaceutical production processes. Since biopharmaceuticals are produced in living organisms, the production process involves up to hundreds of factors determining the product quality; see a simplified illustration in Figure 1 . The production process includes the main unit operations: (1) media preparation, (2) inoculum fermentation, (3) main fermentation, (4) centrifugation(s), (5) chromatography/purification, (6) filtration, (7) fill and finish, and (8) quality control. Steps (1)-(3) belong to upstream cell culture, Steps (4)- (6) belong to downstream target protein purification, and Steps (7)-(8) are for finished drug filling/formulation and final product quality control testing.
The interactions of many factors impact the variability of drug quality; see the fishbone representation of the production process in Figure 1 . In general, these factors can be divided into CPPs and CQAs; see the definitions of CPPs/CQAs in ICH Q8(R2). CPP: At each process unit operation, CPPs are defined as those parameters whose variability has an impact on critical quality and therefore should be monitored and controlled to ensure the process produces the desired quality. Figure 1 : A general biomanufacturing process (Walsh, 2013) .
CQA: A physical, chemical, biological, or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product quality.
Since the raw material attributes are outputs of release materials, they should be considered along with CPPs as impacting process variability.
We represent the variability of any bio-drug critical quality attribute with a random variable (r.v.), denoted by Y . It depends on the random inputs, denoted by X, including selected CPPs/CQAs and other variables introduced in the production process operations (e.g., contamination), denoted by e. Thus, we model the complex interactions of inputs (X, e) and production process impacting on the response by Y = g(X, e|θ θ θ ), where g(·) is a unknown function specified by parameters θ θ θ . The proposed framework can be naturally extended to a vector of responses.
There are two types of uncertainty: stochastic uncertainty (inherent variability of biopharmaceutical production process, i.e., random inputs X and e) and model risk (i.e., limited knowledge on statistical models for (X, e) and function g(·|θ θ θ ) representing the complex interactions). We can control the impact of stochastic uncertainty by improv-ing the production process CPPs/CQAs specifications/control and reduce the model risk through process monitoring and data collection.
To produce a successful batch, there could exist more than 100 factors that need to be considered (Otto et al., 2014) . We explore the causal relationships of underlying physical mechanics causing the interdependence of raw material quality, production process, and bio-drug properties in safety and efficacy. We further develop a BN with parameters θ θ θ modeling the complex probabilistic interdependence, Y = g(X, e|θ θ θ ). We measure the variability of product quality by the output variance, Var(Y ). The contribution of any random input from X and e to Var(Y ) can be quantified by variance-based sensitivity measures. In Section 2.1, we review relevant sensitivity measures, especially focusing on the SV utilized in this paper. Then, before providing the detailed presentation in Sections 3 and 4, we summarize and provide the insights of the proposed production process risk and sensitivity analysis framework accounting for both stochastic uncertainty and model risk in Section 2.2.
Variance-based Sensitivity Measures -Shapley Value
Since hundreds of factors could impact on the product critical attributes, we want to identify those inputs that can reduce the output variance Var(Y ) the most. The contribution of each input, W k in W = (X, e) with k ∈ K , to the output variance relies on probabilistic dependence and structural interactions, where K represents the index set of all inputs in W. Here, the probabilistic dependence represents the underlying interdependence among different inputs (e.g., the CQAs of raw materials and in-process products) and the structural interactions are induced by the complex production process logic. Two most commonly used variance-based sensitivity measures are: (1) the first-
] that considers the variance reduction when we fix W k ; and (2) the total effect T k ≡ E[Var(Y |W −k )] that considers the expected remaining variance when all other inputs, denoted by W −k , are fixed. However, both measures fail to appropriately quantify the sensitivity when there exist probabilistic dependence and/or structural interaction among inputs (Song et al., 2016) .
In this paper, we consider the SV, a new variance-based sensitivity measure introduced by Owen (2014) . It can overcome the limitations of first-order effect and total effect measures. SV was originally introduced to evaluate the performance of a player in a cooperative game from game theory (Shapley, 1953) . In the proposed framework, it is used to quantify the contribution of each random input W k to the output variance
where K = |W| denotes the total number of random inputs and |J | is the size of index subset J from K /{k}; see the description and motivation of SV in Owen (2014) and Song et al. (2016) .
, we put equal weight to all possible sizes of subsets (s = 0, 1, . . . , K − 1) and also equal weight to all possible subsets of size s. The cost function c(J ) represents the variance of Y induced by random inputs in any subset W J . Here, we set the cost function c(J ) to be the expected remaining variance of response Y when all other input factors W −J = W K \J are fixed,
Then, c(J ∪ {k}) − c(J ) is the expected increment of Var[Y |W W W −J ] induced by including W k into the set W J . Therefore, Sh(W k ) defined in Equation (1) can be interpreted as the average variance Var(Y ) increment induced by including W k into all possible subsets W J , which allows us to appropriately account for probabilistic dependence and structural interaction.
The main benefits of SV over first-order and total effect sensitivity measures include: (1) the uncertainty contributions sum up to total variance of output; (2) SV can automatically account for probabilistic dependence and structural interactions occurring in the complex production process; and (3) combing SV with BN (represented by BN-SV) can facilitate the appropriate and interpretable risk and sensitivity analysis since BN is built based on underlying physical mechanics causing the interdependence of raw material quality, production process, and bio-drug properties.
Summary of Proposed Process Risk and Sensitivity Framework
In Section 3, we first explore the causal relationships of CPPs/CQAs of raw materials/in-process materials/API and develop a BN specified by parameters θ θ θ . Since we often have limited batch data, it can efficiently model the complex probabilistic interdependence of production process and improve the interpretability. Then, we derive the variance decomposition, Var(Y |θ θ θ ) = ∑ X k Sh(X k |θ θ θ ) + ∑ e k Sh(e k |θ θ θ ), where the SVs, Sh(X k |θ θ θ ) and Sh(e k |θ θ θ ), measure the contribution of any CPP/CQA X k ∈ X and other factor e k ∈ e to Var(Y |θ θ θ ). Then, the criticality, defined by p W k ,Y (θ θ θ ) ≡ production process influences the estimation uncertainty of Sh(W k ). It can be used to guide the knowledge improvement through process monitoring and data collection.
In sum, the proposed framework can provide systematic production process risk analysis and assess the criticality or contribution of each CPP/CQA to the output variance. It accounts for the impact from model risk. Thus, the framework can provide reliable guidance on CPPs/CQAs monitoring and specifications, as well as quality control for raw materials, intermediate and final products, so that we can efficiently improve the stability of integrated biopharmaceutical production process.
Integrated Production Process Risk Analysis
Here we introduce an end-to-end production process risk analysis. In Section 3.1, we explore the causal relationships and introduce a relational graph to meaningfully connect all sources of data collected from various process unit operations. Then, in Section 3.2, we develop a probabilistic knowledge graph or Bayesian network modeling the complex interdependence between raw material quality, production process, and bio-drug properties in safety and efficacy. In Section 3.3, we propose the BN-SV risk analysis, assess the criticality of each CPP/CQA or any other factor, and identify the main sources of uncertainty contributing the most to the product quality variation; see the algorithm for production process risk analysis in Appendix D.
Relational Graphical Model for Production Process
Based on the interactions of CPPs/CQAs and other factors in each process unit operation and also connections among production steps, we develop a relational graphical model for biopharmaceutical production process from raw materials to finished drug substance; see Figure 2 for illustration. In the graph, nodes represent factors (i.e., CPPs and CQAs) impacting on the product quality. The directed edges model the inputoutput dependence in each process unit and also the interdependence among different production steps. Each big dashed box in Figure 2 illustrates one process unit opera- 
Bayesian Network Development for Production Process
Based on the relational graph introduced in Section 3.1, we develop a BN probabilistic graphical model composing of random variables and their conditional dependencies via directed edges. For biopharmaceutical production processes, it can characterize the probabilistic interdependence between CPPs and CQAs of raw materials, intermediate product/materials, and API.
Bayesian Network Modeling Development Illustrated with An Example
Without loss of generality, we use a simple example including two production steps (say media preparation and main fermentation) in Figure 3 to illustrate the probabilis-tic graphical model development. It is based on the causal relationships and the interactions between CPPs and CQAs. Each node represents a CPP/CQA with a r.v. X modeling its variability. Each directed edge with parameter β i j represents the impact of parent node X i on child node X j . The pattern-fill nodes (X 1 , X 2 , X 3 ) represent the CPPs.
The solid fill nodes (X 6 , X 7 ) represent the monitored CQAs of intermediate materials and drug products. The nodes X 4 and X 5 represent the underlying complete quality status of media and drug product after main fermentation. The CQAs X 6 and X 7 represent the partial information of quality variables X 4 and X 5 . Except the CPPs X 1 , X 2 , X 3 , the impacts from other factors (i.e., uncontrollable factors) introduced during media preparation and main fermentation are modeled through e 4 and e 5 . Since X 4 and X 5 are hidden and also it is hard to uniquely specify the underlying properties of media and product, they could lead to the identification issue. Thus, we simplify and transform the relational graphical model to a graph without hidden nodes, depicted in the right panel of Figure 3 . The CQA X 6 only carries the partial information of the underlying media quality X 4 , and e 6 accounts for the impact from factor e 4 on X 6 . Combining with other factor e 5 , the impact of remaining media properties on the CQA X 7 is modeled through e 7 .
According to the right plot in Figure 3 , the sources of uncertainty impacting on the variability of X 7 include the process parameters X 1 , X 2 , X 3 and other factors e 6 , e 7 . In each process unit operation, we have CPPs X 1 , X 2 as inputs and CQA X 6 as output for the first step, and have CQA X 6 and CPP X 3 as inputs and X 7 as output for the second step. To study the impact of each CPP on the CQA of interest (e.g., X 6 and X 7 ), we can decompose the variance of X 6 and X 7 into the contributions from X 1 , X 2 and X 3 , and remaining parts coming from e 6 and e 7 . In this way, we can identify the main sources of uncertainty and quantify their impacts, which can guide the CPPs/CQAs specifications and the quality control to improve the product quality stability.
Since there are often limited batch data, in Section 3.2.2, we develop a Gaussian Bayesian network modeling the probabilistic interdependence of production process.
Then, we derive a variance decomposition and propose a systematic BN-SV based risk analysis to estimate the criticality of each CPP/CQA in Section 3.3.
Gaussian Bayesian Network Model Development
We consider a probabilistic graphical model with m + 1 nodes representing the interdependence of CPPs/CQAs (X), bio-product critical quality attribute (Y or X m+1 ) and other factors (e). Let the first m p nodes representing CPPs X p = {X 1 , X 2 , . . . , X m p }, the next m a nodes representing CQAs X a = {X m p +1 , X m p +2 , . . . , X m }, and the last node representing the response Y X m+1 with m = m p + m a . We construct the linear Gaussian model of the marginal and conditional distributions for each node as follows:
where Pa(X k ) denotes the parent nodes of X k , and we assume
, and linear coefficients β β β = {β jk ; k = m p +1, . . . , m+ 1 and X j ∈ Pa(X k )}, the conditional distribution for each CQA node X k ,
For any CPP node X k without parent nodes, Pa(X k ) is an empty set and P(X k |Pa(X k ))
∼ N (0, 1) and (5) becomes
Thus, the joint distribution characterizing the interdependence of CPPs and CQAs involved in the production process can be written,
CPPs and CQAs Criticality Assessment
Given the BN parameters θ θ θ = (µ µ µ,v v v 2 ,β β β ), we present the BN-SV based risk analysis for the end-to-end production process and further quantify the criticality of each random input through measuring its contribution to the product quality variance Var(X m+1 ).
CPPs Impact on CQAs of Intermediate and Final Products
We derive the SV quantifying the contribution of each random input from CPPs X p and other factors e to Var(X m+1 ). Suppose X p and e are independent with each other.
According to the Gaussian BN model presented in (3) and (4), we can derive
where the weight coefficient of any CPP X k to CQA X n with k ≤ m p < n ≤ m + 1,
the weight coefficient of any e k to a CQA node X n with m p < k < n ≤ m + 1,
. . . β n−1,n ; (8) and γ nn = 1 for any n; see the derivation for (6) in Appendix A. The weight coefficient γ kn accounts for all paths from node X k to node X n in the BN.
dom inputs, including the variability from raw materials and production process. Denote the index set K = {1, 2, . . . , m + 1}. Then, the SV for the k-th input factor W k is,
Based on (6), we compute the cost function c
and Sh(e k |θ θ θ ) = γ 2 k,m+1 v 2 k for any other factor e k with k = m p + 1, . . . , m + 1. Therefore, we can decompose the variance of drug substance attribute X m+1 and estimate the contribution from each random input from X p and e,
Equation (9) can be used to identify the dominant factors in X p and e contributing the most to the product quality variance, which can guide the parameters specification to improve the production process stability. As a result, given the BN parameters θ θ θ , the criticality of any input W k can be quantified by
In addition, we can assess the impact of inputs on any intermediate product CQA, say X i with m p < i < m + 1. Let X p (X i ) denote a set containing all CPPs from previous process unit operations impacting on Var(X i |θ θ θ ). For example in Figure 3 (b), we consider the subgraph {X 1 , X 2 , X 6 } and then X p (X 6 ) = {X 1 , X 2 }. Following the similar derivation as that for (6), we have
We can compute the SV measuring the contribution from each factor X k or e k on the variance of CQA X i :
Thus, we can decompose the variance of CQA X i to the contribution from each source of uncertainty as
CQAs and CPPs Impact on Final Product or Intermediate CQA
Here we consider the partial production process including one or multiple process unit operations. Suppose that we start from certain operation unit and want to estimate the impact of starting CQAs and remaining steps CPPs on the intermediate or final product CQA of interest. For example, in Figure 3 (b), we consider the subgraph {X 3 , X 6 , X 7 } with the starting CQA X 6 carrying some information from previous operation step. We study the impacts of X 6 and CPP X 3 on the variability of CQA X 7 .
Define the complete BN model with parameters θ θ θ as G(N|θ θ θ ), where the set N = {X 1 , . . . , X m+1 } includes all nodes. Suppose the part of production process of interest is represented by a subgraph G(N |θ θ θ (N )) having the node set denoted by N ⊆ N with size n = |N | and the index set denoted by K . We define the set including the starting Then each remaining CQA node X j ∈ N /(X a (N ) ∪ X p (N )) has the corresponding variation factor e j . Denote the set of e j 's in the subgraph as e(N ). Without loss of generality, suppose there is a node X i ∈ N (m p < i ≤ m + 1) without succeeding nodes in N .
We quantify the contributions of random inputs for the subgraph, including starting CQAs and CPPs, to Var(X i |θ θ θ ). Following the idea similar with (6), we obtain that
Notice that CQAs in X a (N ) could be dependent on each other. The Shapley value used for risk analysis can correctly account for both probabilistic dependence and
k ∈ K } represent all random inputs in the subgraph. For any index subset J ⊂ K , by applying (11), we get
Suppose any CPP X k ∈ X p (N ) or factor e k ∈ e(N ) is independent with other inputs in
When both W k 1 = X k 1 and W k 2 = X k 2 are CQAs belonging to X a (N ), the covariance can be computed by using the linear representation in (10),
see the derivation in Appendix B. Then, for each W k and J ⊂ K /{k}, we can obtain
where Var(X k |θ θ θ ) is the variance of starting CQAs X k and it can be calculated by applying (11) or estimated by using the real-world data. Then, the SV of each input W k on the drug quality CQA X i with m p < i ≤ m + 1 can be calculated as follows:
The derivation of (13) is provided in Appendix C. Thus, we have the variance decomposition:
The criticality of W k on X i can be measured by
Uncertainty Quantification and Sensitivity Analysis
Since the "correct" BN parameters θ θ θ c are unknown, given finite real-world data X , there exists the model risk (MR) characterizing our limited knowledge on the underlying probabilistic interdependence of raw material quality, production process, and bio-drug safety and efficacy. To study the impact of MR on the production process risk analysis and CPPs/CQAs criticality assessment, we propose the BN-SV-MR based UQ and SA which can guide the risk-and science-based process monitoring and data collection. In Section 4.1, we develop the Bayesian learning, derive the posterior p(θ θ θ |X ) and provide a Gibbs sampler to generate posterior samples, θ θ θ 
Bayesian Learning for Model Risk Quantification
We first study the case with R batches of complete production process data, denoted
Without strong prior information, we consider the following non-informative prior,
where Inv-Γ denotes the inverse-gamma distribution. Given the data X , by applying the Bayes' rule, we can obtain the posterior distribution
quantifying the estimation uncertainty of the BN model characterizing the probabilistic interdependence of production process.
To develop a Gibbs sampler for the posterior distribution in (16), we derive the conditional posterior for each parameter in
the set of direct succeeding or child nodes of node X i . We first derive the conditional posterior for the coefficient β i j ,
where θ
. Then, we derive the conditional posterior for v 2 i = Var[X i |Pa(X i )] with i = 1, 2, . . . , m + 1,
where κ
After that, we derive the conditional posterior for the mean parameter µ i with i = 1, 2, . . . , m + 1 for any CPP/CQA,
where µ
The Gibbs sampler iteratively draws the posterior samples of (µ µ µ,v v v 2 ,β β β ) by applying the conditional posterior distributions given in (17), (18), and (19) until convergence (Gelman et al. 2004 ).
Besides the case with complete production data, we often have additional incomplete batch data. Since the lead time for biopharmaceutical production is lengthy (Otto et al., 2014) , we can have some batches in the middle of production. In addition, the bio-drug quality requirements are restricted, especially for human drugs. Following the quality control, we could discard some batches after main fermentation or even in the middle of downstream purification. Thus, we provide the description, derivation and Gibbs sampler (see Algorithm 3) for both cases with complete or mixing data in online Appendix E.1.2.
Uncertainty Quantification Accounting for Model Risk
Here we present the UQ to study the overall impact of BN model risk on the produc- 
The posterior variance is used to quantify the overall estimation uncertainty induced
Since we do not have the closed form solutions, we can estimate the posterior mean and variance of Sh(W k ) and p W k ,X m+1 through the sampling approach. By applying the Gibbs sampler in online Appendix E, we can generate posterior samples θ θ θ , we can compute Sh(W k | θ θ θ (b) ) following the description in Section 3.3. The expected contribution from W k to the variance of X m+1
). And the overall estimation uncertainty can be estimated by sample variance,
Similarly, we can estimate the expected criticality by E
) and estimate the overall estimation uncertainty by
(21)
Sensitivity Study of Risk Analysis to Model Risk
In this section, we propose the BN-SV-MR based sensitivity analysis, and also provide the UQ and SA procedure in Algorithm 1. It allows us to analyze the effect of model risk on the production process risk analysis and criticality assessment for each CPP/CQA. Steps (1) 
is the set containing nodes located along paths from W k to X m+1 ; see Section 3.3. Notice that µ µ µ has no impact on Sh(W k |θ θ θ ). Since SV can appropriately account for the probabilistic dependence characterized by p(θ θ θ |X ) and structural interactions, we can measure the contribution from any parameter θ ∈ θ θ θ (W k , X m+1 ) through the posterior variance decomposition,
The proposed BN-SV-MR sensitivity analysis can provide the comprehensive and interpretable understanding on how the model risk or knowledge limitation over each related part of production process (i.e., represented by parameter θ ∈ θ θ θ (W k , X m+1 )) impacts on the system risk analysis. Output:
(1) Call Algorithm 3 in Appendix E.1.3 to obtain the posterior samples
) with b = 1, 2, . . . , B for UQ and θ θ θ
(2) Call Algorithm 2 in Appendix D to compute Sh(W k | θ θ θ (b) ) and criticality p W k ,X m+1 ( θ θ θ (b) ) for b = 1, 2, . . . , B;
(3) Calculate the overall estimation uncertainty by using Var * (20) and (21); (4) Randomly generate N π permutations, π n ∼ Π(L k ) with n = 1, . . . , N π ; for Each π n do (5) Set c(P π n (1) (π n )) = 0;
J (J) ) by applying Equations (17) (9) Set θ θ θ
with some constant integer h to reduce the correlation between consecutive samples; (10) Compute c(P π n ( +1) (π n )) by Equations (25) and (27); else (11) Set c(P π n ( +1) (π n )) = Var * [Sh(W k )|X ] and Var * [p W k ,X m+1 |X ]; (12) Compute ∆ π n ( ) c(π n ) = c(P π n ( +1) (π n )) − c(P π n ( ) (π n ));
(13) Estimate Sh * θ [ Sh(W k )| X ] and Sh * θ p W k ,X m+1 X by using Equations (26) and (28).
Then, we derive SV, Sh
, to measure the contribution from the estimation uncertainty of θ . Denote the size of relevant BN parameters by L k = |θ θ θ (W k , X m+1 )| and denote the index set by L k . Thus, θ θ θ (W k , X m+1 ) = θ θ θ L k . We further denote any subset by θ θ θ J ⊂ θ θ θ (W k , X m+1 ) with size J = |θ θ θ J | and the corresponding index set J = {J (1), J (2), . . . , J (J)} ⊂ L k . For any J ⊂ L k , the cost function is given as,
where θ θ θ L k −J = θ θ θ L k \J . Denote a permutation of L k as π and define the set P (π) as the index set preceding in π. The SV can be rewritten as,
where Π(L k ) denotes the set of all L k ! permutations of L k .
The number of all possible subsets J could grow exponentially as L k increase.
To address this computational issue, we use the Monte Carlo sampling approach, Ap-proShapley, suggested by Song et al. (2016) and Castro et al. (2009) , by estimating the Shapley value in (23) by
where N π denotes the number of permutations π 1 , . . . , π N π randomly generated from Π(L k ) and ∆ c(π n ) = c(P (π n ) ∪ { }) − c(P (π n )) is the incremental posterior variance Var * [Sh(W k )|X ] induced by including the -th BN parameter input in P (π n ).
To efficiently compute ∆ c(π n ), according to Song et al. (2016) , we compute c(·)
in an order of exact location in permutation π n . Assume the permutation index set π n = {π n (1), π n (2), . . . , π n (L k )}, we compute c(P π n ( ) (π n )) as the order of π n ( ) for = 1, . . . , L, where c(P π n (1) (π n )) = c( / 0) = 0, c(P π n (L k +1) (π n )) = c(π n ) = Var * [Sh(W k )|X ], and P π( j+1) denotes P π( j) (π) ∪ {π( j)} for 0 < j < L k . Then we can compute the incremental variance related to each θ π n ( ) for = 1, . . . , L k : ∆ π n ( ) c(π n ) = c(P π n ( +1) (π n )) − c(P π n ( ) (π n )). Since {θ π n (1) , θ π n (2) . . . , θ π n (L k ) } θ θ θ π n is just a permutation of θ θ θ L k , it is equivalent as computing ∆ c(π n ) for all θ under permutation π n .
We can not analytically compute c(J ) in (22) and a Monte Carlo sampling approach is developed to estimate it. Since the posterior samples obtained from the Gibbs sampler in online Appendix E.1.3 can not be directly used to estimate L k −J , X ). More specifically, we set the initial value θ θ θ
J . In each t-th MCMC iteration, given the previous sample
, we apply the Gibbs sampling to sequentially generate one sample from the conditional posterior for each θ J ( ) ∈ θ θ θ J with = 1, . . . , |J |,
. By repeating this procedure, we can get samples θ θ θ (24), we can quantify the contribution from the estimation uncertainty on
where ∆ c(π n ) = c(P (π n ) ∪ { }) − c(P (π n )) and it is equivalent with computing ∆ π n ( ) c(π n ) = c(P π n ( +1) (π n )) − c(P π n ( ) (π n )) for all = 1, . . . , L k . Similarly, for CPP/CQA criticality assessment, we can estimate the cost function,
L k −J )/B I . Then, we estimate the contribution from the estimation uncertainty of θ on the criticality assessement,
(28)
Empirical Study
To study the performance of the proposed framework, we consider the production process example for a monoclonal antibody (mAbs) bio-drug. The production procedure starts from main fermentation to API, including the main operation steps:
(1) main fermentation, (2) centrifugation, (3) chromatography/purification, and (4) filtration. The simplified relational graph for this production procedure is provided in To study the performance of the proposed framework, we generate the simulated production process data X , which mimics the "real-world data collection." The BN Figure 4 : Relational graph for an antibody bio-drug API production process.
with parameters θ θ θ c = (µ µ µ c , (v v v 2 ) c ,β β β c ) characterizing the underlying risk and interdependence is used for data generation, which is built on the biomanufacturing domain knowledge; see the detailed setting in online Appendix F. To assess the performance of the proposed framework, we assume that the true parameter values are unknown.
We empirically study the convergence of BN parameter inference in Appendix G.
Risk Analysis and Criticality Assessment of CPPs/CQAs
In the real applications, the amount of biopharmaceutical production batch data could be limited. In the following empirical study, we generate the data X with size R = 30 to study the performance of the proposed risk and sensitivity analysis framework. For any CQA X i of interest, at each posterior sample θ θ θ , we follow Algorithm 2 in Appendix D to assess the criticality of CPPs/CQAs and other factors by applying Equation (14). Then, we can estimate the expected criticality for any input W k ∈ {X p (N ) ∪ X a (N ) ∪ e(N )}. Specifically, in the k-th macroreplication, we first generate the "real-world" batch data
∼ p(θ θ θ |X (k) ) for k = 1, . . . , K and b = 1, . . . , B, with K = 20 and B = 1000, and then record the results in terms of percentage (%) in Tables 1 and 2. The BN model risk is characterized by the posterior p(θ θ θ |X ) and its impact on the CPPs/CQAs criticality assessment can be quantified by the posterior standard deviation 
). In Tables 1 and 2, we record the results of SD in terms of percentage (%) in the bracket.
For the example shown in Figure 4, quality. This information can be used to guide the production process quality control.
In addition, according to Table 2 , compared with bioburden X 7 , the CQAs impurities and protein X 5 and X 6 contribute relatively higher to the following intermediate product and final product CQAs variation.
Uncertainty Quantification and Sensitivity Analysis
Here we consider the product protein content X 20 in Figure 4 to illustrate the performance of the proposed sensitivity analysis. Based on the results in Table 1 , the CPPs X 4 and X 13 have the dominant contributions to the variance of output X 20 and they also have the relatively high estimation uncertainty. Thus, we conduct the BN-SV-MR sensitivity analysis to get the comprehensive information on how the BN model risk impacts on the criticality assessment for p X 4 ,X 20 and p X 13 ,X 20 .
Given the data X , we have the posterior variance decomposition studying the criticality estimation error induced by the model risk,
Then, we can estimate the relative contribution from
In the k-th macro-replication, given the data X (k) , we can estimate the contribution from each θ by using Sh * θ p W k ,X i ( θ θ θ ) X (k) and Var * p(θ θ θ |X ) p W k ,X i ( θ θ θ ) X (k) which is estimated by using N π = 500, B O = 5 and B I = 20; see Song et al. (2016) for the selection of sampling parameter setting. Thus, we have EP θ (p W k ,X i ) ≡
The parameters contributing to the estimation of Sh 20 (X 4 ) include v 2 4 and 18 linear coefficients β β β on the paths from node X 4 to node X 20 . The parameters contributing to the estimation of Sh 20 (X 13 ) include v 2 13 and 6 linear coefficients β β β located on the paths from X 13 to X 20 . Due to the space limit, we only present the top five parameters contributing most to the estimation uncertainty of criticality p X 4 ,X 20 and p X 13 ,X 20 , and aggregate the results for remaining parameters. The sensitivity analysis results, EP θ (p W k ,X i ) ± SE EP θ (p W k ,X i ) , for p X 4 ,X 20 and p X 13 ,X 20 are shown in Table 3 , where SE stands for the standard error (SE). Notice that the parameters that contribute the most to the estimation error of the criticality p X 4 ,X 20 and p X 13 ,X 20 are the variance parameters of CPPs (v 2 4 and v 2 13 ). The estimation errors of linear coefficients have similar and relatively small contributions. This information can guide the production process monitoring and data collection to efficiently reduce the estimation uncertainty of criticality assessment and improve our knowledge on the underlying probabilistic interdependence of the biopharmaceutical production process. 
Conclusions
Driven by the critical challenges in biomanufacturing, we propose a new BN based risk and sensitivity analysis framework to facilitate the production process learning and stability control. Since hundreds of factors could impact on the product quality and the amount of real-world batch data is often very limited, we explore the causal relationships and develop a BN characterizing the production process probabilistic interdependence. Considering SV can correctly account for probabilistic dependence and structural interactions, we propose the BN-SV based risk analysis to assess the criticality of each random input on the variance of product quality attributes. Given limited real-world batch data, there exists the model risk. We further introduce the BN-SV-MR based UQ and SA that can provide the comprehensive understanding of how the model risk impacts on the end-to-end production process risk analysis and CPPs/CQAs criticality assessment. An antibody bio-drug production case is used to study the performance of the proposed framework.
There are several directions worth further investigation. In this paper, we ignore the risk induced by the model family selection error. How to quantify and incorporate this source of uncertainty will be considered in the future research. In addition, built on this study, we could develop new methodologies that can facilitate the production process forward prediction and backward problem detection.
Appendix A. Detailed Derivation of Equation (6) In order to show Equation (6), we consider more general results as following,
for n = m p +1, . . . , m+1, where γ k,n is given as Equations (7) and (8). Notice according to linear Gaussian model (4), we can write X m p +1 = µ m p +1 + ∑ m p k=1 β k,m p +1 (X k − µ k ) + e m p +1 , where β k,m p +1 = 0 for k / ∈ Pa(X m p +1 ). Suppose Equation (A.1) holds for all n = m p + 1, . . . , n 0 . For n = n 0 + 1, by applying linear Gaussian model, we have
Step (A.2) follows by applying (A.1).
Step (A.3) follows by applying Equations (7) and (8). By mathematical induction, we can conclude that Equation (A.1) holds for all n = m p + 1, . . . , m + 1. (12) According to the linear representation (10), for any X k 1 , X k 2 ∈ X a (N ), the covariance,
Appendix B. Detailed Derivation of Equation
since CPPs X ∈ X p and error terms e are mutually independent with each other.
Appendix C. Detailed Derivation of Equation (13) We consider W k and J ⊂ K /{k}. For J = / 0, we have
For |J | = m with m = 1, . . . , n − 1, we have
Step (C.1) holds because the number of all subsets J with size m is n −1 m . In Step (C.2), we shift the order of sums over J and . Then, Step (C.3) holds because given W , the number of subset {J : |J | = m and ∈ J } is n −2 m −1 . So, we get the Shapley value,
The last step is obtained by applying Equation (12).
Appendix D. Procedure for Production Process Risk Analysis
Given the BN parameters θ θ θ , we summarize the procedure for production process BN-SV based risk analysis in Algorithm 2. Suppose that we consider several consecutive operation steps corresponding to the (sub)graph G(N |θ θ θ (N )) with N ⊆ N, and we are interested in a single response X i with m p < i ≤ m + 1. Our objective is to quantify the contribution of each random input in G(N |θ θ θ (N )) to Var(X i |θ θ θ ). For the complete production process, we have N = N and X i = X m+1 .
Algorithm 2: Procedure for Production Process BN-SV Based Risk Analysis Input: BN parameters θ θ θ , subgraph G(N |θ θ θ (N )), response node X i . Output: Variance decomposition of X i in terms of all random inputs within G(N |θ θ θ (N )).
(1) Identify node sets X a (N ), X p (N ) and e(N ) representing the random inputs in the subgraph G(N |θ θ θ (N )); see Section 3.3.2; (2) Calculate the Shapley value Sh i (W k |θ θ θ ) with W k = X k or e k by using Equation (13), which measures the contribution from W k to the variance of response CQA X i ; (3) Provide the variance decomposition of Var(X i |θ θ θ ) by using Equation (14), and obtain the criticality of W k on the variance of X i :
. Second, we derive the conditional posterior distribution for the variance parameter
Third, we derive the conditional posterior distribution of mean parameter µ i with i = 1, 2, . . . , m + 1 for any CPP and CQA,
. Knowledge Learning for Cases with Mixing Data
Except the case with complete production data discussed in Section Appendix E.1.1, we consider the cases with additional incomplete data corresponding to certain "Top Sub-Graph", denoted by G(N |θ θ θ (N )) with N ⊆ N, such that any CQA node X j ∈ N has Pa(X j ) ⊂ N . Since batch data collected from biopharmaceutical production process are usually limited, we want to fully utilize both complete and incomplete data to estimate the BN model parameters and improve our knowledge of production process.
Without loss of generality, we consider the real-world data including two data sets X = {X 1 , X 2 } with the complete data X 1 = {(x (r 1 )
1 , x (r 1 ) 2 , . . . , x (r 1 ) m+1 ) for r 1 = 1, 2, . . . , R 1 } and the incomplete data X 2 = {(x (r 2 ) i : X i ∈ N ) for r 2 = R 1 + 1, R 1 + 2, . . . , R}, where R = R 1 + R 2 . Our approach can be easily extended to cases with multiple incomplete data sets. We use the same prior distribution p(µ µ µ,v v v 2 ,β β β ) as shown in Equation (15). Given the mixing data X = {X 1 , X 2 }, we can derive the posterior distribution of θ θ θ ,
For β i j with X j / ∈ N or v 2 i and µ i with node X i / ∈ N , the conditional posterior is the same as complete data case and we can utilize Equations (17), (18) and (19) by replacing X with X 1 .
Thus, to derive the full Gibbs sampler, we only need to provide the updated conditional posterior accounting for those nodes included in the incomplete data set X 2 . We first derive the conditional posterior distribution for weight parameter β i j with X j ∈ N .
Then, we derive the conditional posterior distribution for v 2 i with X i ∈ N ,
After that, we derive the conditional posterior for mean parameter µ i with X i ∈ N ,
Pa(X j ) ),
k − µ k ) for r = 1, 2, . . . , R. Here for illustration, we have only provided the conditional posteriors with two datasets X 1 and X 2 . These derivations can be easily extended to similar cases with multiple datasets collected from complete graph and different top sub-graphs.
Appendix F. Simulated Biopharmaceutical Production Data
To study the performance of proposed framework, we generate the simulated production process data X , which mimics the "real-world data collection." The BN with parameters θ θ θ c characterizing the underlying production process interdependence is used for data generation, which is built according to the biomanufacturing domain knowledge. The ranges of CPPs/CQAs are listed Table F (14), the corresponding parameter v c i can be computed through back-engineering. For the complex interdependence, Table F .5 provides the relative associations with levels (i.e., high, median, low) between input CPPs/CQAs with output CQAs in each operation unit, which is built based on the "cause-and-effect matrix" in Mitchell (2013) . For the high, median and low association between X i to X j , we set the coefficient β c i j = 0.9, 0.6, 0.3 respectively. Thus, we can specify the underlying true parameters θ θ θ c = (µ µ µ c , (v v v 2 ) c ,β β β c ). To mimic the "real-world" data collection, we generate the production batch data X using the BN model with θ θ θ c . Then, to assess the performance of proposed framework, we assume that the true parameter values are unknown. To study the performance of proposed framework, we generate the simulated production process data X , which mimics the "real-world data collection." The BN with parameters θ θ θ c = (µ µ µ c , (v v v 2 ) c ,β β β c ) characterizing the underlying risk and interdependence is used for data generation, which is built on the biomanufacturing domain knowledge; see the detailed setting in online Appendix Appendix F.
To assess the performance of proposed framework, we assume that the true parameter values are unknown. We empirically study the convergence of BN parameter inference. In each k-th macro-replication, we first mimic the "real-world" production batch data collection through generating X (k) = {X Table G .6. As the size of real-world data R increases, the average MSE decreases, which implies the posterior samples obtained by Gibbs sampling procedure can converge to the true parameters. 
